Advertisement

Adult Langerhans Cell Histiocytosis

  • Michael Girschikofsky
  • Abdellatif Tazi
Chapter

Abstract

Most of the knowledge regarding the diagnosis and treatment of adult Langerhans cell histiocytosis (LCH) patients is derived from pediatric studies. Adult LCH patients are often evaluated by physicians who focus only on the most obviously affected organ without sufficient evaluation of other systems, which may lead to an erroneous diagnosis in some patients. In addition, treatment with pediatric-based regimens, often referred to as standard therapy, seems to be less effective and sometimes more toxic in adults.

The published literature on adult LCH lacks a comprehensive discussion on the differences between pediatric and adult patients, and it is still debatable what and how much can be extrapolated from the younger age cohort. Isolated primary pulmonary LCH, in almost all cases associated with smoking, is a common presenting pattern in adults and has particular clinico-radiographic and treatment features that warrant its characterization as a separate entity.

Keywords

Langerhans Histiocytosis Adult Pulmonary 

References

  1. 1.
    Institute NC. Langerhans Cell Histiocytosis Treatment–Health Professional Version. September 25, 2015 [updated September 25, 2015; cited March 22, 2016]; Available from: http://www.cancer.gov/types/langerhans/hp/langerhans-treatment-pdq#link/_141_toc.
  2. 2.
    Arico M, Girschikofsky M, Genereau T, Klersy C, McClain K, Grois N, et al. Langerhans cell histiocytosis in adults. Report from the international registry of the Histiocyte society. Eur J Cancer. 2003;39(16):2341–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Minkov M, Potschger U, Grois N, Gadner H, Dworzak MN. Bone marrow assessment in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2007;49(5):694–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Girschikofsky M, Arico M, Castillo D, Chu A, Doberauer C, Fichter J, et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of euro-Histio-net. Orphanet J Rare Dis. 2013;8:72.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Gadner H, Minkov M, Grois N, Potschger U, Thiem E, Arico M, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013;121(25):5006–14.CrossRefPubMedGoogle Scholar
  6. 6.
    Mourah S, Lorillon G, Meignin V, Vercellino L, de Margerie-Mellon C, Pages C, et al. Dramatic transient improvement of metastatic BRAF(V600E)-mutated Langerhans cell sarcoma under treatment with dabrafenib. Blood. 2015;126(24):2649–52.CrossRefPubMedGoogle Scholar
  7. 7.
    Hervier B, Haroche J, Arnaud L, Charlotte F, Donadieu J, Neel A, et al. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood. 2014;124(7):1119–26.CrossRefPubMedGoogle Scholar
  8. 8.
    Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in multiple Nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373(8):726–36.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Tazi A. Adult pulmonary Langerhans’ cell histiocytosis. Eur Respir J. 2006;27(6):1272–85.CrossRefPubMedGoogle Scholar
  10. 10.
    Arico M, Nichols K, Whitlock JA, Arceci R, Haupt R, Mittler U, et al. Familial clustering of Langerhans cell histiocytosis. Br J Haematol. 1999;107(4):883–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Oh Y, Morimoto A, Shioda Y, Imamura T, Kudo K, Imashuku S. High serum osteopontin levels in pediatric patients with high risk Langerhans cell histiocytosis. Cytokine. 2014;70(2):194–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Berres ML, Lim KP, Peters T, Price J, Takizawa H, Salmon H, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014;211(4):669–83.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Zhou W, Wu H, Han Y, Wang S, Dong Y, Wang Q. Preliminary study on the evaluation of Langerhans cell histiocytosis using F-18-fluoro-deoxy-glucose PET/CT. Chin Med J. 2014;127(13):2458–62.PubMedGoogle Scholar
  14. 14.
    Prayer D, Grois N, Prosch H, Gadner H, Barkovich AJ. MR imaging presentation of intracranial disease associated with Langerhans cell histiocytosis. AJNR Am J Neuroradiol. 2004;25(5):880–91.PubMedGoogle Scholar
  15. 15.
    Obert J, Vercellino L, Van Der Gucht A, de Margerie-Mellon C, Bugnet E, Chevret S, et al. 18F-fluorodeoxyglucose positron emission tomography-computed tomography in the management of adult multisystem Langerhans cell histiocytosis. Eur J Nucl Med Mol Imaging. 2016;20:598.Google Scholar
  16. 16.
    Grois N, Potschger U, Prosch H, Minkov M, Arico M, Braier J, et al. Risk factors for diabetes insipidus in langerhans cell histiocytosis. Pediatr Blood Cancer. 2006;46(2):228–33.CrossRefPubMedGoogle Scholar
  17. 17.
    Chellapandian D, Shaikh F, van den Bos C, Somers GR, Astigarraga I, Jubran R, et al. Management and outcome of patients with Langerhans cell Histiocytosis and single-bone CNS-risk lesions: a multi-institutional retrospective study. Pediatr Blood Cancer. 2015;62(12):2162–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Putters TF, de Visscher JG, van Veen A, Spijkervet FK. Intralesional infiltration of corticosteroids in the treatment of localised langerhans’ cell histiocytosis of the mandible report of known cases and three new cases. Int J Oral Maxillofac Surg. 2005;34(5):571–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Kriz J, Eich HT, Bruns F, Heyd R, Schafer U, Haverkamp U, et al. Radiotherapy in langerhans cell histiocytosis – a rare indication in a rare disease. Radiat Oncol. 2013;8:233.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Braier J, Rosso D, Pollono D, Rey G, Lagomarsino E, Latella A, et al. Symptomatic bone Langerhans cell Histiocytosis treated at diagnosis or after reactivation with indomethacin alone. J Pediatr Hematol Oncol. 2014;11:100.Google Scholar
  21. 21.
    Sivendran S, Harvey H, Lipton A, Drabick J. Treatment of Langerhans cell histiocytosis bone lesions with zoledronic acid: a case series. Int J Hematol. 2011;93(6):782–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Cantu MA, Lupo PJ, Bilgi M, Hicks MJ, Allen CE, McClain KL. Optimal therapy for adults with Langerhans cell histiocytosis bone lesions. PLoS One. 2012;7(8):e43257.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Caputo R. A text atlas of Histiocytic syndromes. London: Informa Health Care; 1998.Google Scholar
  24. 24.
    Lindahl LM, Fenger-Gron M, Iversen L. Topical nitrogen mustard therapy in patients with Langerhans cell histiocytosis. Br J Dermatol. 2012;166(3):642–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Sakai H, Ibe M, Takahashi H, Matsuo S, Okamoto K, Makino I, et al. Satisfactory remission achieved by PUVA therapy in Langerhans cell histiocytosis in an elderly patient. J Dermatol. 1996;23(1):42–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Imafuku S, Shibata S, Tashiro A, Furue M. Cutaneous Langerhans cell histiocytosis in an elderly man successfully treated with narrowband ultraviolet B. Br J Dermatol. 2007;157(6):1277–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Failla V, Wauters O, Caucanas M, Nikkels-Tassoudji N, Nikkels AF. Photodynamic therapy for multi-resistant cutaneous Langerhans cell histiocytosis. Rare Tumors. 2010;2(2):e34.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Furudate S, Fujimura T, Kambayashi Y, Kawano M, Ogasawara K, Tsukada A, et al. Successful treatment of adult onset Langerhans cell histiocytosis with bi-weekly administration of pegylated interferon-alpha. Acta Derm Venereol. 2014;94(5):611–2.CrossRefPubMedGoogle Scholar
  29. 29.
    McClain KL, Kozinetz CA. A phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr Blood Cancer. 2007;48(1):44–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Szturz P, Adam Z, Rehak Z, Koukalova R, Slaisova R, Stehlikova O, et al. Lenalidomide proved effective in multisystem Langerhans cell histiocytosis. Acta Oncol. 2012;51(3):412–5.CrossRefPubMedGoogle Scholar
  31. 31.
    Rao A, Chu A. Langerhans cell histiocytosis: treatment of cutaneous disease with azathiopine. Br J Dermatol. [Poster Presentation (P24)]. 2013;169(Suppl 1):30.Google Scholar
  32. 32.
    Steen AE, Steen KH, Bauer R, Bieber T. Successful treatment of cutaneous Langerhans cell histiocytosis with low-dose methotrexate. Br J Dermatol. 2001;145(1):137–40.CrossRefPubMedGoogle Scholar
  33. 33.
    Chu T. Langerhans cell histiocytosis. Australas J Dermatol. 2001;42(4):237–42.CrossRefPubMedGoogle Scholar
  34. 34.
    Makras P, Kaltsas G. Langerhans cell histiocytosis and pituitary function. Endocrine. 2015;48(3):728–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Kaltsas GA, Powles TB, Evanson J, Plowman PN, Drinkwater JE, Jenkins PJ, et al. Hypothalamo-pituitary abnormalities in adult patients with langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment. J Clin Endocrinol Metab. 2000;85(4):1370–6.CrossRefPubMedGoogle Scholar
  36. 36.
    Jian F, Bian L, Sun S, Yang J, Chen X, Chen Y, et al. Surgical biopsies in patients with central diabetes insipidus and thickened pituitary stalks. Endocrine. 2014;47(1):325–35.CrossRefPubMedGoogle Scholar
  37. 37.
    Grois N, Fahrner B, Arceci RJ, Henter JI, McClain K, Lassmann H, et al. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr. 2010;156(6):873–81. 81 e1.Google Scholar
  38. 38.
    Reed ML, Merriam GR, Kargi AY. Adult growth hormone deficiency – benefits, side effects, and risks of growth hormone replacement. Front Endocrinol (Lausanne). 2013;4:64.Google Scholar
  39. 39.
    Makras P, Alexandraki KI, Chrousos GP, Grossman AB, Kaltsas GA. Endocrine manifestations in Langerhans cell histiocytosis. Trends Endocrinol Metab. 2007;18(6):252–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Buchler T, Cervinek L, Belohlavek O, Kantorova I, Mechl M, Nebesky T, et al. Langerhans cell histiocytosis with central nervous system involvement: follow-up by FDG-PET during treatment with cladribine. Pediatr Blood Cancer. 2005;44(3):286–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Grois N, Prayer D, Prosch H, Lassmann H. Neuropathology of CNS disease in Langerhans cell histiocytosis. Brain. 2005;128(Pt 4):829–38.CrossRefPubMedGoogle Scholar
  42. 42.
    Imashuku S, Fujita N, Shioda Y, Noma H, Seto S, Minato T, et al. Follow-up of pediatric patients treated by IVIG for Langerhans cell histiocytosis (LCH)-related neurodegenerative CNS disease. Int J Hematol. 2015;101(2):191–7.CrossRefPubMedGoogle Scholar
  43. 43.
    Idbaih A, Donadieu J, Barthez MA, Geissmann F, Bertrand Y, Hermine O, et al. Retinoic acid therapy in “degenerative-like” neuro-langerhans cell histiocytosis: a prospective pilot study. Pediatr Blood Cancer. 2004;43(1):55–8.CrossRefPubMedGoogle Scholar
  44. 44.
    Allen CE, Flores R, Rauch R, Dauser R, Murray JC, Puccetti D, et al. Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside. Pediatr Blood Cancer. 2010;54(3):416–23.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Chohan G, Barnett Y, Gibson J, Reddel SW, Barnett MH. Langerhans cell histiocytosis with refractory central nervous system involvement responsive to infliximab. J Neurol Neurosurg Psychiatry. 2012;83(5):573–5.CrossRefPubMedGoogle Scholar
  46. 46.
    Imashuku S, Arceci RJ. Strategies for the prevention of central nervous system complications in patients with Langerhans cell Histiocytosis: the problem of neurodegenerative syndrome. Hematol Oncol Clin North Am. 2015;29(5):875–93.CrossRefPubMedGoogle Scholar
  47. 47.
    Alexandraki KI, Makras P, Protogerou AD, Dimitriou K, Stathopoulou A, Papadogias DS, et al. Cardiovascular risk factors in adult patients with multisystem Langerhans-cell histiocytosis: evidence of glucose metabolism abnormalities. QJM. 2008;101(1):31–40.CrossRefPubMedGoogle Scholar
  48. 48.
    Makras P, Terpos E, Kanakis G, Papatheodorou A, Anastasilakis AD, Kokkoris P, et al. Reduced bone mineral density in adult patients with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2011;58:819–22.CrossRefPubMedGoogle Scholar
  49. 49.
    Attakkil A, Thorawade V, Jagade M, Kar R, Parelkar K. Isolated Langerhans Histiocytosis in thyroid: thyroidectomy or chemotherapy? J Clin Diagn Res. 2015;9(9):XD01–XD3.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Axiotis CA, Merino MJ, Duray PH. Langerhans cell histiocytosis of the female genital tract. Cancer. 1991;67(6):1650–60.CrossRefPubMedGoogle Scholar
  51. 51.
    Singhi AD, Montgomery EA. Gastrointestinal tract langerhans cell histiocytosis: a clinicopathologic study of 12 patients. Am J Surg Pathol. 2011;35(2):305–10.CrossRefPubMedGoogle Scholar
  52. 52.
    Abdallah M, Genereau T, Donadieu J, Emile JF, Chazouilleres O, Gaujoux-Viala C, et al. Langerhans’ cell histiocytosis of the liver in adults. Clin Res Hepatol Gastroenterol. 2011;35(6–7):475–81.CrossRefPubMedGoogle Scholar
  53. 53.
    Scanzi J, Goutte M, Teilhet C, Abergel A. When should we consider transplantation in adult patients with sclerosing cholangitis due to multisystem Langerhans’ cell histiocytosis? Dig Liver Dis. 2015;47(2):176–7.CrossRefPubMedGoogle Scholar
  54. 54.
    Das DK, Sheikh ZA, Alansary TA, Amir T, Al-Rabiy FN, Junaid TA. A case of Langerhans’ cell histiocytosis associated with Hodgkin’s lymphoma: fine-needle aspiration cytologic and histopathological features. Diagn Cytopathol. 2016;44(2):128–32.CrossRefPubMedGoogle Scholar
  55. 55.
    Lo WC, Chen CC, Tsai CC, Cheng PW. Isolated adult Langerhans’ cell histiocytosis in cervical lymph nodes: should it be treated? J Laryngol Otol. 2009;123(9):1055–7.CrossRefPubMedGoogle Scholar
  56. 56.
    Elia D, Torre O, Cassandro R, Caminati A, Harari S. Pulmonary Langerhans cell histiocytosis: a comprehensive analysis of 40 patients and literature review. Eur J Intern Med. 2015;26(5):351–6.CrossRefPubMedGoogle Scholar
  57. 57.
    Schini M, Makras P, Kanakis G, Voulgarelis M, Kaltsas G. Cladribine therapy in adults with advanced Langerhans cell histiocytosis. Leuk Lymphoma. 2013;54(7):1541–3.CrossRefPubMedGoogle Scholar
  58. 58.
    Derenzini E, Stefoni V, Pellegrini C, Gandolfi L, Broccoli A, Casadei B, et al. High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience. BMC Cancer. 2015;15:879.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    DiMaggio LA, Lippes HA, Lee RV. Histiocytosis X and pregnancy. Obstet Gynecol. 1995;85(5 Pt 2):806–9.CrossRefPubMedGoogle Scholar
  60. 60.
    Ananthakrishnan S. Diabetes insipidus in pregnancy: etiology, evaluation, and management. Endocr Pract. 2009;15(4):377–82.CrossRefPubMedGoogle Scholar
  61. 61.
    Janku F, Amin HM, Yang D, Garrido-Laguna I, Trent JC, Kurzrock R. Response of histiocytoses to imatinib mesylate: fire to ashes. J Clin Oncol. 2010;28(31):e633–6.CrossRefPubMedGoogle Scholar
  62. 62.
    Xicoy B, Ribera JM, Batlle M, Feliu E. Sustained remission in an adult patient with Langerhans cell histiocytosis following T-cell depleted allogenic cell transplantation. Med Clin (Barc). 2006;127(18):716.Google Scholar
  63. 63.
    Yohe SL, Chenault CB, Torlakovic EE, Asplund SL, McKenna RW. Langerhans cell histiocytosis in acute leukemias of ambiguous or myeloid lineage in adult patients: support for a possible clonal relationship. Mod Pathol. 2014;27(5):651–6.CrossRefPubMedGoogle Scholar
  64. 64.
    Howarth DM, Gilchrist GS, Mullan BP, Wiseman GA, Edmonson JH, Schomberg PJ. Langerhans cell histiocytosis: diagnosis, natural history, management, and outcome. Cancer. 1999;85(10):2278–90.CrossRefPubMedGoogle Scholar
  65. 65.
    Suri HS, Yi ES, Nowakowski GS, Vassallo R. Pulmonary langerhans cell histiocytosis. Orphanet J Rare Dis. 2012;7:16.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Tazi A, de Margerie C, Naccache JM, Fry S, Dominique S, Jouneau S, et al. The natural history of adult pulmonary Langerhans cell histiocytosis: a prospective multicentre study. Orphanet J Rare Dis. 2015;10:30.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Bernstrand C, Cederlund K, Sandstedt B, Ahstrom L, Lundell M, Dahlquist G, et al. Pulmonary abnormalities at long-term follow-up of patients with Langerhans cell histiocytosis. Med Pediatr Oncol. 2001;36(4):459–68.CrossRefPubMedGoogle Scholar
  68. 68.
    Badalian-Very G, Vergilio JA, Degar BA, Rodriguez-Galindo C, Rollins BJ. Recent advances in the understanding of Langerhans cell histiocytosis. Br J Haematol. 2012;156(2):163–72.CrossRefPubMedGoogle Scholar
  69. 69.
    Mourah S, How-Kit A, Meignin V, Gossot D, Lorillon G, Bugnet E, et al. Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis. Eur Respir J. 2016;47(6):1785–96.CrossRefPubMedGoogle Scholar
  70. 70.
    Roden AC, Hu X, Kip S, Parrilla Castellar ER, Rumilla KM, Vrana JA, et al. BRAF V600E expression in Langerhans cell histiocytosis: clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases. Am J Surg Pathol. 2014;38(4):548–51.CrossRefPubMedGoogle Scholar
  71. 71.
    Yousem SA, Dacic S, Nikiforov YE, Nikiforova M. Pulmonary Langerhans cell histiocytosis: profiling of multifocal tumors using next-generation sequencing identifies concordant occurrence of BRAF V600E mutations. Chest. 2013;143(6):1679–84.CrossRefPubMedGoogle Scholar
  72. 72.
    Tazi A, Marc K, Dominique S, de Bazelaire C, Crestani B, Chinet T, et al. Serial computed tomography and lung function testing in pulmonary Langerhans’ cell histiocytosis. Eur Respir J. 2012;40(4):905–12.CrossRefPubMedGoogle Scholar
  73. 73.
    Baqir M, Vassallo R, Maldonado F, Yi ES, Ryu JH. Utility of bronchoscopy in pulmonary Langerhans cell histiocytosis. J Bronchology Interv Pulmonol. 2013;20(4):309–12.CrossRefPubMedGoogle Scholar
  74. 74.
    Harari S, Torre O, Cassandro R, Taveira-DaSilva AM, Moss J. Bronchoscopic diagnosis of Langerhans cell histiocytosis and lymphangioleiomyomatosis. Respir Med. 2012;106(9):1286–92.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Tazi A, Soler P, Hance AJ. Adult pulmonary Langerhans’ cell histiocytosis. Thorax. 2000;55(5):405–16.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Kim HJ, Lee KS, Johkoh T, Tomiyama N, Lee HY, Han J, et al. Pulmonary Langerhans cell histiocytosis in adults: high-resolution CT-pathology comparisons and evolutional changes at CT. Eur Radiol. 2011;21(7):1406–15.CrossRefPubMedGoogle Scholar
  77. 77.
    Tazi A, de Margerie-Mellon C, Vercellino L, Naccache JM, Fry S, Dominique S, et al. Extrathoracic investigation in adult patients with isolated pulmonary langerhans cell histiocytosis. Orphanet J Rare Dis. 2016;11:11.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Vassallo R, Ryu JH, Schroeder DR, Decker PA, Limper AH. Clinical outcomes of pulmonary Langerhans’-cell histiocytosis in adults. N Engl J Med. 2002;346(7):484–90.CrossRefPubMedGoogle Scholar
  79. 79.
    Feuillet S, Louis L, Bergeron A, Berezne A, Dubreuil ML, Polivka M, et al. Pulmonary Langerhans cell histiocytosis associated with Hodgkin’s lymphoma. Eur Respir Rev. 2010;19(115):86–8.CrossRefPubMedGoogle Scholar
  80. 80.
    Mendez JL, Nadrous HF, Vassallo R, Decker PA, Ryu JH. Pneumothorax in pulmonary Langerhans cell histiocytosis. Chest. 2004;125(3):1028–32.CrossRefPubMedGoogle Scholar
  81. 81.
    Grobost V, Khouatra C, Lazor R, Cordier JF, Cottin V. Effectiveness of cladribine therapy in patients with pulmonary Langerhans cell histiocytosis. Orphanet J Rare Dis. 2014;9(1):191.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Lorillon G, Bergeron A, Detourmignies L, Jouneau S, Wallaert B, Frija J, et al. Cladribine is effective against cystic pulmonary Langerhans cell histiocytosis. Am J Respir Crit Care Med. 2012;186(9):930–2.CrossRefPubMedGoogle Scholar
  83. 83.
    Le Pavec J, Lorillon G, Jais X, Tcherakian C, Feuillet S, Dorfmuller P, et al. Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. Chest. 2012;142(5):1150–7.CrossRefPubMedGoogle Scholar
  84. 84.
    Dauriat G, Mal H, Thabut G, Mornex JF, Bertocchi M, Tronc F, et al. Lung transplantation for pulmonary langerhans’ cell histiocytosis: a multicenter analysis. Transplantation. 2006;81(5):746–50.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Internal Medicine I, (Hemostasis, Hematology and Stem Cell Transplantation and Medical Oncology), Ordensklinikum Linz – Elisabethinen HospitalLinzAustria
  2. 2.Assistance Publique-Hôpitaux de Paris, Saint-Louis Hospital, National Reference Center for Langerhans Cell Histiocytosis, Pulmonary DepartmentParisFrance
  3. 3.University Paris Diderot, Sorbonne Paris Cité, Inserm UMR-1153 (CRESS), Biostatistics and Clinical Epidemiology Research Team (ECSTRA)ParisFrance

Personalised recommendations